尚荣医疗(002551) - 2025 Q2 - 季度业绩预告

Performance Forecast Overview The company forecasts a net loss of 7 million to 9.5 million yuan for H1 2025, a significant year-over-year decline H1 2025 Performance Forecast vs. Prior Year Period | Metric | H1 2025 Estimated | Prior Year Period | Year-over-Year Change | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | Loss 7 million - 9.5 million yuan | Profit 14.0266 million yuan | ↓ 149.91% - 167.73% | | Net Profit After Non-Recurring Items | Loss 11.6594 million - 14.1594 million yuan | Profit 2.3089 million yuan | ↓ 604.98% - 713.25% | | Basic Earnings Per Share | Loss 0.008 - 0.011 yuan/share | Profit 0.0166 yuan/share | - | Analysis of Performance Change Reasons Loss attributed to lower medical engineering revenue, reduced export medical consumables profit, and a sharp decline in non-recurring income - Revenue recognized from completed medical professional engineering projects decreased by 72% compared to the prior year period[4] - Sales volume and profit margins of export medical consumable products further declined[4] - Non-operating income from government subsidies and write-offs of receivables decreased by approximately 90% compared to the prior year period[4] Important Statement and Risk Warning This performance forecast is a preliminary, unaudited estimate; final data in 2025 semi-annual report, investors urged to note risks - The financial data related to this performance forecast has not been pre-audited by a certified public accountant[3] - This performance forecast is a preliminary estimate by the company's finance department; final data will be based on the '2025 Semi-Annual Report'[5] - The company advises investors to be aware of investment risks and to rely on information published in designated media (e.g., China Securities Journal, Securities Times, and Juchao Information Network)[6]